Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For the month of May 2004

Commission File Number 000-28966

Biacore International AB (publ)

C/o Biacore International SA
Puits-Godet 12
CH-2000 Neuchatel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.

Form 20-F  X
Form 40-F

Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act
of 1934.

No   X

If "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): Not applicable.


Uppsala, Sweden, May 14, 2004.

Biacore International AB (Biacore) today announced that it has requested that
its American Depositary Receipts under its trading symbol "BCOR" be delisted
from the Nasdaq National Market, effective as of May 21, 2004.

This action will not affect the continuing listing of Biacore's shares on

Biacore's shares were registered with the SEC and listed on Nasdaq National
Market in 1996 in the form of ADRs, each representing one ordinary share. At
such time as the ADRs are delisted from Nasdaq National Market, registered
holders will be contacted by the Company's Depositary Bank in respect of the
ADRs, JP Morgan, with instructions regarding how to proceed.

About Biacore

Biacore is a global market leader in Surface Plasmon Resonance (SPR) technology
based systems with its own sales operations in the U.S., across Europe, Japan,
Australia and New Zealand. A strong patent portfolio protects Biacore's SPR
technology, which gives unique real-time insights into biomolecular
interactions. Target groups for the Company's products consist primarily of
medical and life science research laboratories and pharmaceutical and
biotechnology companies around the world. Biacore is focusing on drug discovery
and development as its prime areas for future growth. The Company currently has
seven systems on the market, the most important of which are:  Biacore(r)S51 for
applications downstream of high-throughput screening (HTS) including rapid
characterization of HTS hits and comprehensive pre-clinical evaluation of lead
compounds, Biacore(r)3000, which offers flexibility in key life science research
and drug discovery applications upstream of HTS, and Biacore(r)C which is
specifically designed for compliant concentration analysis of biopharmaceuticals
in GLP/GMP applications. A new SPR array system, which will provide higher
information content, is expected to reach the market in 2004.

Based in Uppsala, Sweden, the Company is listed on Stockholmsborsen and Nasdaq
in the U.S. In 2003 the Company had sales of SEK 515.5 million and an operating
income of SEK 29.5 million.

Further information on Biacore can be found on the web:


Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

Dated: June 11, 2004
Biacore International AB (publ)
By: Lars-Olov Forslund
Name: Lars-Olov Forslund
Title: Chief Financial Officer